AMAG Pharmaceuticals has provided a safety update on Feraheme (ferumoxytol injection) indicating that serious adverse events have been reported at a rate consistent with that contained in the Prescribing Information.

The FDA has approved Oleptro (trazodone HCl extended-release tablets, from Labopharm), a once-daily formulation of trazodone, for the treatment of major depressive disorder (MDD) in adults.

Auxilium Pharmaceuticals announced the approval of Xiaflex (collagenase clostridium histolyticum) for the treatment of adult Dupuytren's contracture patients with a palpable cord.

The FDA has approved Medicis' hyaluronic acid with lidocaine dermal fillers, Restylane-L and Perlane-L.

The FDA has approved Juvéderm XC (hyaluronic acid and lidocaine [preservative-free] injectable gel, from Allergan) dermal filler for injection into the mid-to-deep dermis for correction of moderate to severe facial wrinkles and folds (eg, nasolabial folds).

Dyax Corporation announced the availability of Kalbitor (ecallantide for injection) for the treatment of acute attacks of hereditary angioedema in patients ≥16 years of age.

Upsher-Smith Laboratories announced the introduction of a new formulation of PreNexa, a once-daily prescription prenatal vitamin formulated with algal-oil, plant-based docosahexaenoic acid (DHA).

The FDA has approved Lamictal XR (lamotrigine extended-release tablets, from GlaxoSmithKline) as a once daily, add-on therapy for epilepsy in patients ≥13 years of age with primary generalized tonic-clonic seizures.

GlaxoSmithKline announced that the FDA has approved Tykerb (lapatinib tablets) in combination with letrozole (Femara, from Novartis) as a first-line, all-oral regimen for the treatment of postmenopausal women with hormone receptor (HR) positive metastatic breast cancer that overexpresses the HER2 receptor.

Sato Pharmaceutical has made available over-the-counter Zentrip (meclizine HCl quick-dissolving strips) for the prevention and relief of nausea, vomiting, and dizziness associated with motion sickness.